Technology ID
TAB-757
Oral Treatment of Hemophilia
E-Numbers
E-281-2001-0
Co-Inventors
Alpan, Oral
Matzinger, Polly (NIAID)
Kamala, Tirumalai (NIAID)
Velander, William (Virginia Tech Intellectual Properties, Inc)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In vivo data available (animal)
Lead IC
NIAID
ICs
NIAID
This invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.
Commercial Applications
- Oral-based treatment for hemophilia A or B
Competitive Advantages
- Less invasive than current modes of treatment
- Reduced inflammatory response
- Immunotolerization against future bleeding episodes
Licensing Contact: